Syndecan-2 is a Key Regulator of Transforming Growth Factor Beta 2/Smad2-mediated Adhesion in Fibrosarcoma Cells
Overview
Molecular Biology
Authors
Affiliations
Fibrosarcoma is a rare malignant tumor originating from fibroblasts. Transforming growth factor beta 2 (TGFβ2) has been established to regulate processes correlated to fibrosarcoma tumorigenesis. In this study, we investigated the possible participation of syndecan-2 (SDC-2), a cell membrane heparan sulfate (HS) proteoglycan on these TGFβ2 functions. Our results demonstrate that the inhibition of SDC-2 expression by short interfering RNA (siSDC2) abolished TGFβ2-dependent HT1080 cell adhesion (P ≤ 0.01). In parallel, the downregulation of SDC-2 significantly inhibited TGFβ2-induced Smad2 phosphorylation (P ≤ 0.01). The immunoflourescence signal of TGF receptor III as well as its protein expression was decreased in SDC-2-deficient cells. The enhancement of adhesion molecules integrin β1 (P ≤ 0.01) and focal adhesion kinase expression, induced by TGFβ2 treatment (P ≤ 0.001), was markedly inhibited in SDC-2-defficient cells (P ≤ 0.01). Conclusively, the obtained data suggest that SDC-2 modulates TGFβ2 transcriptional regulation via Smad signaling to facilitate fibrosarcoma cell adhesion.
Extracellular Matrix Components and Mechanosensing Pathways in Health and Disease.
Berdiaki A, Neagu M, Tzanakakis P, Spyridaki I, Perez S, Nikitovic D Biomolecules. 2024; 14(9).
PMID: 39334952 PMC: 11430160. DOI: 10.3390/biom14091186.
Proestling K, Husslein H, Hudson Q, Witzmann-Stern M, Widmar B, Bago-Horvath Z Int J Mol Sci. 2024; 25(1).
PMID: 38203610 PMC: 10778601. DOI: 10.3390/ijms25010439.
Matrix Effectors in the Pathogenesis of Keratinocyte-Derived Carcinomas.
Kavasi R, Neagu M, Constantin C, Munteanu A, Surcel M, Tsatsakis A Front Med (Lausanne). 2022; 9:879500.
PMID: 35572966 PMC: 9100789. DOI: 10.3389/fmed.2022.879500.
Syndecan-2 enriches for hematopoietic stem cells and regulates stem cell repopulating capacity.
Termini C, Pang A, Li M, Fang T, Chang V, Chute J Blood. 2021; 139(2):188-204.
PMID: 34767029 PMC: 8759530. DOI: 10.1182/blood.2020010447.
Burrell K, Nguyen N, Deering-Rice C, Memon T, Almestica-Roberts M, Rapp E Mol Pharmacol. 2021; 100(3):295-307.
PMID: 34290137 PMC: 11037451. DOI: 10.1124/molpharm.121.000280.